Cocrystal Pharma, Inc.
About Cocrystal Pharma, Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2020
- $2.0M
- Net income
- -$8.8M
- Total assets
- $9.7M
- Market cap
- $13.3M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $9.0M
- Operating income
- -$9.0M
- Net income
- -$8.8M
- EPS (basic)
- $-0.78
- EPS (diluted)
- $-0.78
Balance sheet
- Total assets
- $9.7M
- Current assets
- $8.1M
- Total liabilities
- $3.4M
- Current liabilities
- $2.2M
- Shareholders’ equity
- $6.3M
Cash flow
- Operating cash flow
- -$8.2M
- Investing cash flow
- -$12.0K
- Financing cash flow
- $8.2M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $13.3M
- EPS (diluted)
- $-0.78
- Shares outstanding
- 13.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 1, 2008
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $8.8M in FY2020.
- Trading 48% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Cocrystal Pharma, Inc..
Write a review
News about Cocrystal Pharma, Inc.
News & sentiment via Polygon.io
